These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 2345710

  • 1. Clinical pharmacology of recombinant human erythropoietin (r-HuEPO).
    Flaharty KK.
    Pharmacotherapy; 1990; 10(2 ( Pt 2)):9S-14S. PubMed ID: 2345710
    [Abstract] [Full Text] [Related]

  • 2. [Comparison of the efficacy and tolerance of recombinant human erythropoietin between intravenous and subcutaneous administration in chronic hemodialysis. Prospective multicenter study].
    Ruedin P, Stoerman C, Pechère-Bertschi A, Leski M.
    Nephrologie; 1992; 13(2):87-92. PubMed ID: 1608502
    [Abstract] [Full Text] [Related]

  • 3. Erythropoietin response and route of administration.
    Taylor JE, Belch JJ, Fleming LW, Mactier RA, Henderson IS, Stewart WK.
    Clin Nephrol; 1994 May; 41(5):297-302. PubMed ID: 8050210
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics and haematological parameters of recombinant human erythropoietin after subcutaneous administrations in horses.
    Souillard A, Audran M, Bressolle F, Jaussaud P, Gareau R.
    Biopharm Drug Dispos; 1996 Dec; 17(9):805-15. PubMed ID: 8968532
    [Abstract] [Full Text] [Related]

  • 5. Comparison between intravenous recombinant human erythropoietin and subcutaneous injection in Thai hemodialysis patients.
    Trakarnvanich T, Thitiarcharkul S.
    J Med Assoc Thai; 2004 Sep; 87(9):1041-7. PubMed ID: 15516004
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB, Dowell JA, Pratt RD.
    Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
    [Abstract] [Full Text] [Related]

  • 7. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration.
    Besarab A, Flaharty KK, Erslev AJ, McCrea JB, Vlasses PH, Medina F, Caro J, Morris E.
    J Am Soc Nephrol; 1992 Mar; 2(9):1405-16. PubMed ID: 1627763
    [Abstract] [Full Text] [Related]

  • 8. Clinical efficacy of recombinant human erythropoietin in hemodialysis patients.
    Mohini R.
    Semin Nephrol; 1989 Mar; 9(1 Suppl 1):16-21. PubMed ID: 2648516
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease.
    Macdougall IC, Robson R, Opatrna S, Liogier X, Pannier A, Jordan P, Dougherty FC, Reigner B.
    Clin J Am Soc Nephrol; 2006 Nov; 1(6):1211-5. PubMed ID: 17699350
    [Abstract] [Full Text] [Related]

  • 10. [Successful treatment of anemia in hemolysis patients using recombinant human erythropoietin. Maintenance dosage and serum concentration].
    Stutz B, Rhyner K, Vögtli J, Binswanger U.
    Schweiz Med Wochenschr; 1987 Sep 19; 117(38):1397-402. PubMed ID: 3672079
    [Abstract] [Full Text] [Related]

  • 11. Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure.
    Cowgill LD, James KM, Levy JK, Browne JK, Miller A, Lobingier RT, Egrie JC.
    J Am Vet Med Assoc; 1998 Feb 15; 212(4):521-8. PubMed ID: 9491159
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics and distribution of recombinant erythropoietin in rats.
    Kinoshita H, Ohishi N, Kato M, Tokura S, Okazaki A.
    Arzneimittelforschung; 1992 Feb 15; 42(2):174-8. PubMed ID: 1610430
    [Abstract] [Full Text] [Related]

  • 13. Characterization of the anaemia of chronic renal failure and the mode of its correction by a preparation of human erythropoietin (r-HuEPO). An investigation of the pharmacokinetics of intravenous erythropoietin and its effects on erythrokinetics.
    Cotes PM, Pippard MJ, Reid CD, Winearls CG, Oliver DO, Royston JP.
    Q J Med; 1989 Feb 15; 70(262):113-37. PubMed ID: 2594953
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Correction of anaemia in haemodialysis patients with recombinant human erythropoietin.
    Boran M, Dalva I, Yazicioğlu A, Akbay E, Cetin S.
    Int Urol Nephrol; 1993 Feb 15; 25(2):197-203. PubMed ID: 8365853
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men.
    Flaharty KK, Caro J, Erslev A, Whalen JJ, Morris EM, Bjornsson TD, Vlasses PH.
    Clin Pharmacol Ther; 1990 May 15; 47(5):557-64. PubMed ID: 2188770
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.